Published in final edited form as:

Curr Opin Clin Nutr Metab Care. 2017 March ; 20(2): 145–152. doi:10.1097/MCO.0000000000000353.

Resolving Inflammation by using Nutrition Therapy: Roles for Specialized Pro-Resolving Mediators

Lucy V Norling¹, Lucy Ly^{1,2}, and Jesmond Dalli^{1,2}

¹The William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom

²QMUL Lipid Mediator Unit, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom

Structured Abstract

Purpose of Review—Inflammation is a unifying component of many of the diseases that afflict western civilizations. Nutrition therapy and in particular essential fatty acid (EFA) supplementation is one of the approaches that is currently in use for the treatment and management of many inflammatory conditions. The purpose of the present review is to discuss the recent literature in light of the discovery that essential fatty acids are converted by the body to a novel genus of lipid mediators, termed specialized proresolving mediators (SPM).

Recent findings—The SPM genus is composed of four mediator families, the lipoxins resolvins, protectins and maresins. These molecules potently and stereoselectively promote the termination of inflammation, tissue repair, and regeneration. Recent studies suggest that in disease, SPM production becomes dysregulated giving rise to a status of failed resolution. Of note, several studies found that omega-3 fatty acid supplementation, at doses within the recommended daily allowance, led to increases in several SPM families that correlate with enhanced white blood cell responses in humans and reduced inflammation in mice.

Summary—Given the potent biological actions of SPM in organ protection and promoting bacterial clearance, nutritional therapies enriched in omega-3 fatty acids hold promise as a potential co-therapy approach when coupled with functional lipid mediator profiling.

Keywords

Specialized proresolving mediators; Resolution pharmacology; Essential fatty acids; immunity; chronic inflammation

Introduction

Resolution of acute inflammation is a protective, highly coordinated cellular and biochemical process that paves the way to repair and regeneration of damaged tissues and

Author for correspondence: Jesmond Dalli or Lucy V Norling, The William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, United Kingdom. Jesmond Dalli: j.dalli@qmul.ac.uk, Lucy V Norling: l.v.norling@qmul.ac.uk, Phone no: +44-2078828263.

Conflict of interest: The authors declare no conflict of interest.

re-establishment of host function. This fundamental process orchestrated by a novel genus of lipid mediators termed specialized pro-resolving mediators (SPM) consists of the essential fatty acid derived (EFA) lipoxins, resolvins, protectins and maresins. These molecules are enzymatically produced in many organs in the human body at levels commensurate with their biological actions (Figure 1) and carry defined stereochemistries that are central for their bioactions (for a detailed review on the biosynthetic mechanisms see(17, 18)). The biological actions of these novel mediators in controlling inflammation are distinct to current therapeutics. Indeed, while drugs in clinical use are designed to inhibit inflammation and block leukocytic recruitment, SPM's act by counter-regulating the production of proinflammatory mediators (cytokines, chemokines and inflammatory eicosanoids), limiting leukocytic infiltration and promoting leukocyte phenotype switch (for a detailed review see(19)). Therefore, these molecules do not prevent inflammation but rather avert it from becoming uncontrolled and thus promote its termination. In addition, recent studies demonstrate that they actively promote tissue repair and regeneration in the context of infection(20). Given the potent biological actions of these molecules understanding how their biosynthetic pathways become dysregulated during chronic inflammatory diseases and the impact of essential fatty acid (EFA) supplementation on increasing their endogenous production will provide novel and effective ways in nutrition therapy.

Despite the potent actions of SPM and the role of EFA in their biosynthesis, clinical nutrition in the context of the Intensive Care Unit (ICU) is somewhat limited. The scope of the present review is to discuss recent literature and the current pre-clinical and clinical evidence as it pertains to the role of SPM in mediating the host protective actions of EFA supplementation in both health and disease with the aim to identify potential areas for future translation research of EFA nutrition in an ICU context. We will also review the utility of functional lipid mediator profiling in determining the functional impact of immune nutrition, which may help provide a mechanistic basis for the apparently discordant results on the effectiveness of EFA supplementation in the treatment of inflammatory conditions (Figure 2).

Protective actions of SPM and omega-3 EFA in pre-clinical settings

Arthritis

Arthritis is a prototypical chronic inflammatory disease characterized by unabated inflammation that leads to joint destruction and is associated with increased risk of cardiovascular disease. Metabololipidomic profiling of arthritic joints from ω -3 EFA supplemented mice identified elevated levels of SPM including resolvin D1 (7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosaheptaenoic acid)(9). When tested in a murine model of inflammatory arthritis, the stable epimer 17R-resolvin D1 significantly attenuated arthritis severity, cachexia, hind-paw oedema, and paw leukocyte infiltration and shortened the remission interval. Furthermore, 17R-resolvin D1 exhibited novel tissue-protective functions including stimulation of chondrocyte matrix production and protection from cartilage degradation(9). Resolvin D1 also display protective effects in osteoarthritis (OA) pathophysiology. Resolvin D1 counteracted interleukin-1 β (IL-1 β)-induced cyclooxygenase (COX)-2, prostaglandin E₂ (9-oxo-11 α ,15S-dihydroxy-5Z,13E-prostadienoic acid),

inducible nitric oxide synthase, nitric oxide, and matrix metalloproteinase-13 in human OA chondrocytes via suppression of Nuclear Factor- κ B/p65, p38/mitogen-activated protein kinase and c-Jun N-terminal kinase1/2 and prevented human neutrophil elastase-induced cell apoptosis and oxidative stress(21).

Pain is a major symptom of arthritis and related conditions that can significantly affect the quality of a patient's life. Fish oil supplementation significantly reduced subchronic inflammatory pain induced by intraplantar injection of complete freunds adjuvant into rat hind paws. In these experiments, different doses of eicosapentaenoic acid (460-690mg) and docosahexaenoic acid (300-540mg) were found to reduce pain. Protection was associated with reduced tumor necrosis factor-alpha (TNF α) and increased levels of resolvin D1 in supplemented groups thereby indicating that essential fatty acid supplementation may regulate pain via SPM production(22).

Saturated fatty acids such as palmitate can cause muscle atrophy, which in turn may contribute to a debilitating loss of functional independence. A recent finding indicate that docosahexaenoic acid, the biosynthetic precursor of the D-series resolvins including resolvin D1 and 17R-resolvin D1, prevents the catabolic effects of palmitate-induced protein degradation by restoring protein kinase B/Forkhead box O-signalling(23). These studies provide mechanistic substance for the benefits of ω -3 eicosapentaenoic acid supplementation in symptoms associated with arthritis and by limiting the amount of pain relief patients require.

Actions in promoting the clearance of bacterial and viral infections

With the rising incidence in sepsis, which is prone to antibiotic resistance, there is an emphasis in identifying novel therapeutics to combat this fatal condition. Mice fed a high-fat diet (HFD) rich in ω -3 eicosapentaenoic acid for 8 weeks prior to inoculation with *Staphylococcus aureus* had decreased bacterial loads and better survival compared to those fed a HFD rich in saturated fatty acids. Administering doses as low as 1 or 10ng of resolvin D1 or resolvin D2 (7S,16R,17S-trihydroxy-4Z,8E,10Z,12E,14E,19Z-docosahexaenoic acid) to mice given a HFD rich in saturated fatty acid diet for 8 weeks also gave significant protection, increased survival and reduced bacterial loads(24). Recently, a receptor for RvD2 G-protein coupled receptor 18 (GPR18) was identified using unbiased GPR β -arrestin-based screening and functional sensing systems(25). The binding affinity of resolvin D1 was ~10nM, consistent with its bioactive concentration range. In *Escherichia coli* and *S. aureus* infections, resolvin D1 limited polymononuclear (PMN) infiltration, enhanced bacterial clearance and accelerated resolution. These actions were lost in GPR18-deficient mice, providing evidence for a novel Resolvin D2-GPR18 resolution axis that stimulates phagocyte functions to control bacterial infections and protect the host(25).

Recent studies demonstrate that SPM are also effective in regulating response to viral infections including influenza. Influenza viruses remain a critical global health concern and more effective vaccines are needed. Mice immunized with Ovalbumin (OVA) plus 17-HDHA (17-hydroxy-4Z,7Z,10Z,13Z,15E,19Z-docosahexaenoic acid) or with H1N1-derived hemagglutinin protein plus 17-HDHA increased antigen-specific antibody titers(26). Importantly, the 17-HDHA-mediated increase in antibody production was more protective

against live pH1N1 influenza infection, implicating SPM as useful for a potential new vaccine.

Adipose & metabolic syndrome

Fat-1 transgenic mice express the *Caenorhabditis elegans* (*C.elegans*) enzyme that converts ω -6 into ω -3 EFA, and are therefore used as an experimental tool to assess if higher ratios of ω -3: ω -6 EFA contribute to protective responses in various conditions. It was recently reported that Fat-1 transgenic mice are protected from obesity, fasting hyperglycemia, glucose intolerance, and adipose tissue inflammation(27).

Dietary intervention with ω -3 EFA was shown to curb inflammatory and oxidative stress markers related with metabolic syndrome. This was associated with a modulation of lipoxygenase (LOX) and COX activities, reducing proinflammatory arachidonic acid-derived eicosanoids and oxidative stress biomarkers from eicosapentaenoic acid and docosahexaenoic acid (28). In a separate study, treatment with 467 mg/g eicosapentaenoic acid and 365 mg/g docosahexaenoic acid for 20 weeks prevented renal failure associated with metabolic syndrome, which was associated with decreased triglyceride levels and augmented levels of protectin D1 (10R,17S-dihydroxy-4Z,7Z,11E,13E,15Z,19Z-docosahexaenoic acid), resolvin D1, and resolvin D2(29).

A selective increase in levels of anti-inflammatory and proresolving lipid mediators in white adipose tissue was observed in mice fed a high fat diet for 5 weeks that was supplemented with ω -3 EFA (4.3mg eicosapentaenoic acid/14.7mg docosahexaenoic acid per g of diet), reflecting either their association with adipocytes or with stromal vascular cells that gave elevated expression of protectin D1(30).

In a model of diabetic neuropathy, dietary fish oil supplementation for 6 weeks or RvD1 administration (1 ng/g body weight) improved thermal hypoalgesia, motor and sensory nerve conduction velocities, innervation of the cornea and skin, and the retinal ganglion cell complex(31). Resolvin D1 also stimulated neurite outgrowth from primary cultures of dorsal root ganglion neurons(31).

Cardiovascular inflammation

EFA supplementation has for long been associated with improved outcomes in cardiovascular disease. Recent studies demonstrate that ω -EFA supplementation may lead to improved outcomes following myocardial infarction. The role of SPM in mediating these protective actions was tested by blocking enzymes involved in their biosynthesis, COX-2 and 15-LOX. Rats fed a ω -3 EFA rich diet for 10 days before myocardial infarction (MI) and given inhibitors displayed larger infarct sizes than ω -3 diet alone. Moreover, resolvin D1 administration gave significant cardioprotection in these animals, providing evidence for the role of these mediators in observed cardioprotective actions of ω -3 EFA supplementation(32). In addition, supplementation of apolipoprotein E null mice with a diet enriched (0.70%) in ω -3 EFA was protective against proinflammatory and oxidative stress responses following short-term infusion with angiotensin II, which was also associated with elevated plasma resolvin D1 levels(33).

Unresolved inflammation contributes to heart failure following MI. When resolvin D1 was administered alone or incorporated into liposomes this led to improved fractional shortening post-MI. The levels of resolvin D1, resolvin D2, maresin 1 (7R,14S-dihydroxy-4Z,8E,10E,12Z,16Z,19Z-docosahexaenoic) acid and Lipoxin A₄ (5S,6R,15S-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid) were increased in spleens from RvD1 injected mice 5 days post-MI, as well as increased expression of its receptor ALX/FPR2. RvD1 reduced pro-fibrotic genes and collagen deposition in the heart, leading to reduced post-MI fibrosis and thereby reducing the risk of heart failure(34).

Studies in rats given high-fat, high-cholesterol diet for 8 weeks with or without docosahexaenoic acid (3g/day) demonstrated that docosahexaenoic acid supplementation gave lower arterial blood pressure and heart rates and prevented aortic wall thickening. Aortic tissue analysis revealed an increase in docosahexaenoic acid:arachidonic acid ratio and enhanced production of resolvin D2 and resolvin D3 (4S,11R,17S-trihydroxy-5Z,7E,9E,13Z,15E,19Z-docosahexaenoic acid) (35). In a mouse model of carotid ligation, resolvin D2 or Maresin 1 treatment significantly attenuate neointima formation measured at day 14, indicating a protective role of SPM in vascular remodelling(36).

Neuro-protection

Transient global cerebral ischemia, which can result from cardiac arrest or cardiovascular surgery, can cause neuronal death and cognitive defects. Currently, there are no effective preventions or treatments for this condition. Fat-1 transgenic mice were protected from neuronal loss and cognitive deficits induced by global ischemic insult, which correlated with increased production of resolvin D1, suppressed nuclear factor-kappa B activation, and reduced generation of proinflammatory mediators in the hippocampus(37). In separate studies, resolvin D1 administration in experimental autoimmune encephalomyelitis decreased disease progression by suppressing autoreactive T cells and inducing an M2 phenotype of monocytes/macrophages and resident brain microglial cells(38).

Recent studies also demonstrate that eicosapentaenoic acid consumption in the early stage of social isolation suppresses hyperglycemia and hypertriglyceridemia associated with insulin resistance without altering food intake or body weight(39). Docosahexaenoic acid is important for brain function and clinical data indicates that docosahexaenoic acid can improve cognition in very early stages of Alzheimer's disease (AD)(40). Local delivery of docosahexaenoic acid to the brain has proved possible using systemically-administered low-density lipoprotein nanoparticles combined with pulsed focused ultrasound exposures. This treatment modality led to increased levels of resolvin D1 in the brain(41).

Lung inflammation

Neutrophil-mediated acute lung injury from ischemia/reperfusion (I/R) remains a major cause of morbidity and mortality in critical care medicine. Lung A549 cells incubated with eicosapentaenoic acid or docosahexaenoic acid followed by lipopolysaccharide increased levels of Maresin 1 and protectin D1(42). In mice, low-dose inhaled carbon monoxide (125-250 ppm) or resolvin D1 (250-500 ng), reduced PMN-mediated lung injury, neutrophil-platelet interactions, and production of cysteinyl leukotrienes and thromboxane B₂ (9 α ,

11,15S-trihydroxy-5Z,13E-thrombadienoic acid) during ischemia reperfusion(42). Maresin 1 was recently found to display potent broncho-protective actions, significantly decreasing bronchoalveolar lavage neutrophil infiltration and proinflammatory mediators in a model of dust exposure. In addition, maresin 1 was produced during early stages of acid induced inflammation(43) and during the resolution phase of allergic inflammation(44) and promoted the resolution of disease.

Aging

Aging is associated with an overt inflammatory phenotype and physiological decline. In a self-resolving model of peritonitis, aged mice had delayed resolution and reduced SPMs. *Ex vivo* incubation of human monocytes eicosapentaenoic acid:docosahexaenoic acid reprogrammed their lipid mediator phenotype, significantly upregulating SPM production. When these cells were administered to mice at the peak of inflammation, resolution of acute inflammation was accelerated. Administration of nano-proresolving medicines carrying aspirin-triggered resolvin D1 and resolvin D3 to aged mice also reduced inflammation(45). Neuroprotective properties of fish oil were assessed in brains of young (3 months) and aged (24 months) mice. Docosahexaenoic acid levels were significantly lower in blood and brains of aged mice, which were compensated by fish oil administration(46). Together, these results demonstrate a failure in resolution pathways associated with ageing that may be improved by ω -3 EFA supplementation.

Protective actions of SPM and omega-3 EFA in humans

Neuro-protection

The effects of ω -3 EFA supplementation (4-17 months) was assessed in a small group of patients with minor cognitive impairment (MCI) and showed increased monocyte phagocytosis of amyloid-beta(A β). Additionally, resolvin D1, which stimulates A β phagocytosis, increased in 80% of patients with MCI and pre-MCI. This study shows significant immune and biochemical effects of ω -3 EFA supplementation in MCI patients. However, cognitive benefits remain to be tested in a clinical trial(47).

AD is associated with brain inflammation and reduced levels of SPMs. In a randomized, double-blind, placebo-controlled clinical trial on AD patients, 1.7g docosahexaenoic acid and 0.6g EPA were administered daily for 6 months. Plasma levels of arachidonic acid decreased, and docosahexaenoic acid and eicosapentaenoic acid levels increased. Analysis of supernatants from peripheral blood mononuclear cells incubated with A β 1-40 showed unchanged levels of the SPMs lipoxin A₄ and resolvin D1 in the ω -3 EFA supplemented group. In the placebo group there was a significant decrease in the levels of these SPMs, which corresponded to cognitive changes suggesting a role for EFA supplementation in protection from cognitive decline(48).

Metabolic syndrome/Obesity

In a recent clinical trial, the effects of ω -3 EFA supplementation (2.4 g/day for 4 weeks with aspirin 300 mg/day during the last 7 days) on volunteers with metabolic syndrome, which is associated with chronic low-grade inflammation was assessed. SPM precursors/pathway

markers 18-HEPE (18-hydroxy-5Z,8Z,11Z,14Z,16E-eicosapentaenoic acid), 17-HDHA, and 14-HDHA (14S-hydroxy-4Z,7Z,10Z,12E,16Z,19Z-docosahexaenoic acid) were increased after ω -3 PUFA supplementation. However, these were significantly attenuated in the metabolic syndrome group(49). ω -3 EFAs may also reduce low-grade inflammation associated with obesity. Indeed, obese women given a supplementation with 1.8g per day of eicosapentaenoic acid and docosahexaenoic acid for 3 months showed a significant decrease inflammatory markers including monocyte chemoattractant protein-1, and high sensitivity C-reactive protein, fasting triglycerides and insulin. This correlated with increased plasma levels of resolvins and an up-regulation of the resolvin D1 receptor(50).

Healthy volunteers

SPM amounts in their bioactive ranges have been identified in a large number of organ systems including spleen (4), brain (1) and urine (16) (Figure 1) and may be involved in a number of physiological processes. Using functional lipid mediator profiling to measure flux down, each of the major bioactive metabolomes plasma SPM rapidly increase (within 4h) with ω -3 EFA (docosahexaenoic acid/eicosapentaenoic acid) and aspirin intake that also correlated with increased *E. coli* phagocytosis in whole blood(4). Moreover, recent studies demonstrate that ω -3 DPA supplementation (7 days) in healthy volunteers increased plasma resolvin D5_{n-3} DPA (Δ 7,17S-dihydroxy-8E,10Z,13Z,15E,19Z docosapentaenoic acid and Maresin 1, compared with volunteers given EPA or placebo (olive oil)(51). These suggest that ω -3 EFA supplementation may have beneficial actions in healthy volunteers by upregulating systemic SPM levels.

Conclusion

Recent advances in our understanding of resolution mechanisms and SPM regulation by EFA supplementation set the stage for a better understanding of the apparently discordant results obtained in clinical settings with nutritional therapies. The potent biological actions that SPM exert in regulating the host response to both infectious and sterile inflammation imply that EFA supplementation hold great potential in treating patients within the ICU. In order to ensure that this potential is fulfilled future clinical studies assessing the clinical utility of EFA supplementation in regulating processes within inflammation need to take into consideration several factors. These include obtaining empirical evidence for the doses to be used, identifying the optimal supplement composition (including ratios of essential fatty acids as well as other components present) and the form of the EFA that is being utilized (i.e. methylester, ethylester, triglycerides etc) since this will influence their bioavailability and pharmacodynamics. Thus, given the potent actions of SPM and their endogenous protective roles in human disease, functional lipid mediator profiling represents a new and exciting approach for empirically defining optimal dosing and formulations for EFA supplements for designing effective nutritional therapies.

Acknowledgements

None

Financial Support and Sponsorship:

This work was supported by funding from the European Research Council (ERC) under the European Union's Horizon 2020 research (No 677542) and a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant 107613/Z/15/Z both to JD). L.V.N is supported by a Career Development Fellowship 19909 funded by Arthritis Research UK. This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Unit, which is supported and funded by the National Institutes of Health Research.

References

1. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. *J Clin Invest*. 2005; 115(10):2774–83. [PubMed: 16151530] [*Authoritative review on mechanisms of SPM biosynthesis*]
2. Pruss H, Rosche B, Sullivan AB, Brommer B, Wengert O, Gronert K, et al. Proresolutive lipid mediators in multiple sclerosis - differential, disease severity-dependent synthesis - a clinical pilot trial. *PLoS One*. 2013; 8(2):e55859. [PubMed: 23409068]
3. Wang X, Zhu M, Hjorth E, Cortes-Toro V, Eyjolfsson H, Graff C, et al. Resolution of inflammation is altered in Alzheimer's disease. *Alzheimers Dement*. 2015; 11(1):40–50 e1-2. [PubMed: 24530025]
4. Colas RA, Shinohara M, Dalli J, Chiang N, Serhan CN. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. *Am J Physiol Cell Physiol*. 2014; 307(1):C39–54. [PubMed: 24696140]
5. Claria J, Nguyen BT, Madenci AL, Ozaki CK, Serhan CN. Diversity of lipid mediators in human adipose tissue depots. *Am J Physiol Cell Physiol*. 2013; 304(12):C1141–9. [PubMed: 23364264]
6. Keelan JA, Mas E, D'Vaz N, Dunstan JA, Li S, Barden AE, et al. Effects of maternal n-3 fatty acid supplementation on placental cytokines, pro-resolving lipid mediators and their precursors. *Reproduction*. 2015; 149(2):171–8. [PubMed: 25504868]
7. Arnardottir HH, Dalli J, Norling LV, Colas RA, Perretti M, Serhan CN. Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation. *J Immunol*. 2016; 197(6):2362–8. [PubMed: 27534559]
8. Barden AE, Moghaddami M, Mas E, Phillips M, Cleland LG, Mori TA. Specialised pro-resolving mediators of inflammation in inflammatory arthritis. *Prostaglandins Leukot Essent Fatty Acids*. 2016; 107:24–9. [PubMed: 27033423]
9. Norling LV, Headland SE, Dalli J, Arnardottir HH, Haworth O, Jones HR, et al. Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis. *JCI Insight*. 2016; 1(5):e85922. [PubMed: 27158677]
10. Croasdell A, Thatcher TH, Kottmann RM, Colas RA, Dalli J, Serhan CN, et al. Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. *Am J Physiol Lung Cell Mol Physiol*. 2015; 309(8):L888–901. [PubMed: 26301452]
11. Yang J, Eiserich JP, Cross CE, Morrissey BM, Hammock BD. Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. *Free Radic Biol Med*. 2012; 53(1):160–71. [PubMed: 22580336]
12. Dalli J, Colas RA, Quintana C, Barragan-Bradford D, Hurwitz S, Levy BD, et al. Human Sepsis Eicosanoid and Proresolving Lipid Mediator Temporal Profiles: Correlations With Survival and Clinical Outcomes. *Crit Care Med*. 2016
13. Mas E, Croft KD, Zahra P, Barden A, Mori TA. Resolvins D1, D2, and other mediators of self-limited resolution of inflammation in human blood following n-3 fatty acid supplementation. *Clin Chem*. 2012; 58(10):1476–84. [PubMed: 22912397]
14. Arnardottir H, Orr SK, Dalli J, Serhan CN. Human milk proresolving mediators stimulate resolution of acute inflammation. *Mucosal Immunol*. 2016; 9(3):757–66. [PubMed: 26462421]
15. Weiss GA, Troxler H, Klinker G, Rogler D, Braegger C, Hersberger M. High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation. *Lipids Health Dis*. 2013; 12:89. [PubMed: 23767972]

16. Sasaki A, Fukuda H, Shiida N, Tanaka N, Furugen A, Ogura J, et al. Determination of omega-6 and omega-3 PUFA metabolites in human urine samples using UPLC/MS/MS. *Anal Bioanal Chem.* 2015; 407(6):1625–39. [PubMed: 25577352]
17. Serhan CN, Dalli J, Colas RA, Winkler JW, Chiang N. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. *Biochim Biophys Acta.* 2015; 1851(4):397–413. [PubMed: 25139562]
18. Buckley CD, Gilroy DW, Serhan CN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. *Immunity.* 2014; 40(3):315–27. [PubMed: 24656045]
19. Serhan CN, Chiang N, Dalli J. The resolution code of acute inflammation: Novel pro-resolving lipid mediators in resolution. *Semin Immunol.* 2015; 27(3):200–15. [PubMed: 25857211]
20. Dalli J, Chiang N, Serhan CN. Identification of 14-series sulfido-conjugated mediators that promote resolution of infection and organ protection. *Proceedings of the National Academy of Sciences of the United States of America.* 2014; 111(44):E4753–61. [PubMed: 25324525]
21. Benabdoune H, Rondon EP, Shi Q, Fernandes J, Ranger P, Fahmi H, et al. The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis. *Inflamm Res.* 2016; 65(8):635–45. [PubMed: 27056390]
22. Lobo BW, Lima CK, Teixeira MS, Silva NL, Takiya CM, Ramos MF, et al. Fish oil attenuates persistent inflammatory pain in rats through modulation of TNF-alpha and resolvins. *Life Sci.* 2016; 152:30–7. [PubMed: 27012767]
23. Woodworth-Hobbs ME, Hudson MB, Rahnert JA, Zheng B, Franch HA, Price SR. Docosahexaenoic acid prevents palmitate-induced activation of proteolytic systems in C2C12 myotubes. *J Nutr Biochem.* 2014; 25(8):868–74. [PubMed: 24835079]
24. Svahn SL, Ulleryd MA, Grahnmö L, Stahlman M, Boren J, Nilsson S, et al. Dietary Omega-3 Fatty Acids Increase Survival and Decrease Bacterial Load in Mice Subjected to *Staphylococcus aureus*-Induced Sepsis. *Infect Immun.* 2016; 84(4):1205–13. [PubMed: 26857576]
25. Chiang N, Dalli J, Colas RA, Serhan CN. Identification of resolvin D2 receptor mediating resolution of infections and organ protection. *J Exp Med.* 2015; 212(8):1203–17. [PubMed: 26195725]
26. Ramon S, Baker SF, Sahler JM, Kim N, Feldsott EA, Serhan CN, et al. The specialized proresolving mediator 17-HDHA enhances the antibody-mediated immune response against influenza virus: a new class of adjuvant? *J Immunol.* 2014; 193(12):6031–40. [PubMed: 25392529] [*This is the first demonstration that pro-resolving mediators can act as adjuvants in antibody production during viral infections.*]
27. Belchior T, Paschoal VA, Magdalon J, Chimin P, Farias TM, Chaves-Filho AB, et al. Omega-3 fatty acids protect from diet-induced obesity, glucose intolerance, and adipose tissue inflammation through PPARgamma-dependent and PPARgamma-independent actions. *Mol Nutr Food Res.* 2015; 59(5):957–67. [PubMed: 25641959]
28. Dasilva G, Pazos M, Garcia-Egido E, Gallardo JM, Rodriguez I, Cela R, et al. Healthy effect of different proportions of marine omega-3 PUFAs EPA and DHA supplementation in Wistar rats: Lipidomic biomarkers of oxidative stress and inflammation. *J Nutr Biochem.* 2015; 26(11):1385–92. [PubMed: 26320676]
29. Katakura M, Hashimoto M, Inoue T, Al Mamun A, Tanabe Y, Iwamoto R, et al. Omega-3 fatty acids protect renal functions by increasing docosahexaenoic acid-derived metabolite levels in SHR.Cg-Lepr(cp)/NDmcr rats, a metabolic syndrome model. *Molecules.* 2014; 19(3):3247–63. [PubMed: 24642910]
30. Kuda O, Rombaldova M, Janovska P, Flachs P, Kopecky J. Cell type-specific modulation of lipid mediator's formation in murine adipose tissue by omega-3 fatty acids. *Biochem Biophys Res Commun.* 2016; 469(3):731–6. [PubMed: 26707880]
31. Shevalye H, Yorek MS, Coppey LJ, Holmes A, Harper MM, Kardon RH, et al. Effect of enriching the diet with menhaden oil or daily treatment with resolvin D1 on neuropathy in a mouse model of type 2 diabetes. *J Neurophysiol.* 2015; 114(1):199–208. [PubMed: 25925322]
32. Gilbert K, Malick M, Madingou N, Touchette C, Bourque-Riel V, Tomaro L, et al. Metabolites derived from omega-3 polyunsaturated fatty acids are important for cardioprotection. *Eur J Pharmacol.* 2015; 769:147–53. [PubMed: 26550951]

33. Wales KM, Kavazos K, Nataatmadja M, Brooks PR, Williams C, Russell FD. N-3 PUFAs protect against aortic inflammation and oxidative stress in angiotensin II-infused apolipoprotein E^{-/-} mice. *PLoS One*. 2014; 9(11):e112816. [PubMed: 25398022]
34. Kain V, Ingle KA, Colas RA, Dalli J, Prabhu SD, Serhan CN, et al. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. *J Mol Cell Cardiol*. 2015; 84:24–35. [PubMed: 25870158]
35. Morin C, Rousseau E, Blier PU, Fortin S. Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction. *Am J Physiol Heart Circ Physiol*. 2015; 309(1):H93–H102. [PubMed: 25910811]
36. Akagi D, Chen M, Toy R, Chatterjee A, Conte MS. Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. *FASEB J*. 2015; 29(6):2504–13. [PubMed: 25777995]
37. Luo C, Ren H, Wan JB, Yao X, Zhang X, He C, et al. Enriched endogenous omega-3 fatty acids in mice protect against global ischemia injury. *J Lipid Res*. 2014; 55(7):1288–97. [PubMed: 24875538]
38. Poisson LM, Suhail H, Singh J, Datta I, Denic A, Labuzek K, et al. Untargeted Plasma Metabolomics Identifies Endogenous Metabolite with Drug-like Properties in Chronic Animal Model of Multiple Sclerosis. *J Biol Chem*. 2015; 290(52):30697–712. [PubMed: 26546682]
39. Nonogaki K, Yamazaki T, Murakami M, Kaji T. Ingestion of eicosapentaenoic acid in the early stage of social isolation reduces a fibroblast growth factor 21 resistant state independently of body weight in KKA(y) mice. *Biochem Biophys Res Commun*. 2015; 464(2):674–7. [PubMed: 26187667]
40. Heras-Sandoval D, Pedraza-Chaverri J, Perez-Rojas JM. Role of docosahexaenoic acid in the modulation of glial cells in Alzheimer's disease. *J Neuroinflammation*. 2016; 13(1):61. [PubMed: 26965310]
41. Mulik RS, Bing C, Ladouceur-Wodzak M, Munaweera I, Chopra R, Corbin IR. Localized delivery of low-density lipoprotein docosahexaenoic acid nanoparticles to the rat brain using focused ultrasound. *Biomaterials*. 2016; 83:257–68. [PubMed: 26790145]
42. Shinohara M, Kibi M, Riley IR, Chiang N, Dalli J, Kraft BD, et al. Cell-cell interactions and bronchoconstrictor eicosanoid reduction with inhaled carbon monoxide and resolvin D1. *Am J Physiol Lung Cell Mol Physiol*. 2014; 307(10):L746–57. [PubMed: 25217660]
43. Abdunour RE, Dalli J, Colby JK, Krishnamoorthy N, Timmons JY, Tan SH, et al. Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective. *Proc Natl Acad Sci U S A*. 2014; 111(46):16526–31. [PubMed: 25369934]
44. Krishnamoorthy N, Burkett PR, Dalli J, Abdunour RE, Colas R, Ramon S, et al. Cutting edge: maresin-1 engages regulatory T cells to limit type 2 innate lymphoid cell activation and promote resolution of lung inflammation. *J Immunol*. 2015; 194(3):863–7. [PubMed: 25539814]
45. Arnardottir HH, Dalli J, Colas RA, Shinohara M, Serhan CN. Aging delays resolution of acute inflammation in mice: reprogramming the host response with novel nano-proresolving medicines. *J Immunol*. 2014; 193(8):4235–44. [PubMed: 25217168]
46. Afshordel S, Hagl S, Werner D, Rohner N, Kogel D, Bazan NG, et al. Omega-3 polyunsaturated fatty acids improve mitochondrial dysfunction in brain aging--impact of Bcl-2 and NPD-1 like metabolites. *Prostaglandins Leukot Essent Fatty Acids*. 2015; 92:23–31. [PubMed: 24972878]
47. Fiala M, Halder RC, Sagong B, Ross O, Sayre J, Porter V, et al. omega-3 Supplementation increases amyloid-beta phagocytosis and resolvin D1 in patients with minor cognitive impairment. *FASEB J*. 2015; 29(7):2681–9. [PubMed: 25805829] [*Provides the basis for essential fatty acid supplementation in cognitive protection and potential biomarkers to measure efficacy*]
48. Wang X, Hjorth E, Vedin I, Eriksdotter M, Freund-Levi Y, Wahlund LO, et al. Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegaAD study. *J Lipid Res*. 2015; 56(3):674–81. [PubMed: 25616438]
49. Barden AE, Mas E, Croft KD, Phillips M, Mori TA. Specialized proresolving lipid mediators in humans with the metabolic syndrome after n-3 fatty acids and aspirin. *Am J Clin Nutr*. 2015;

- 102(6):1357–64. [PubMed: 26561623] [*This study provides an insight in the potential mechanisms activated by essential fatty acid supplementation in controlling pain in inflammatory arthritis.*]
50. Polus A, Zapala B, Razny U, Gielicz A, Kiec-Wilk B, Malczewska-Malec M, et al. Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. *Biochim Biophys Acta*. 2016; 1861(11):1746–55. [PubMed: 27531277]
51. Markworth JF, Kaur G, Miller EG, Larsen AE, Sinclair AJ, Maddipati KR, et al. Divergent shifts in lipid mediator profile following supplementation with n-3 docosapentaenoic acid and eicosapentaenoic acid. *FASEB J*. 2016 [*Establishes the utility of n-3 docosapentaenoic acid as a potential supplement in treating inflammatory diseases.*]

Key Phrases

- 1) SPM are produced via stereoselective enzymatic from essential fatty acids
- 2) EFA supplementation is associated with increases SPM and improved outcomes in experimental system and humans
- 3) Functional lipid mediator profiling represents a novel and predictive approach to determine the efficacy of EFA supplementation.

Figure 1. SPM's are produced in human organs and tissues.

This figure provides a non-exhaustive list of lipid mediator levels identified in inflamed and non-inflamed human tissues including brain (1), cerebrospinal fluid (2, 3), lymph nodes (4), adipose tissues (5), placenta (6), synovial fluids (7–9), exhaled breath condensate (10), sputum (11), plasma (4, 12), serum (2, 4, 13), milk (14, 15), spleen (4) and urine (16), along with the ranges that these mediators were identified in each tissue or organ system. The biological actions for the identified mediators with human primary cells are in the femtomolar to nanomolar ranges.

Figure 2. Functional lipid mediator profiling provides a snapshot of the flux down of each of the major bioactive metabolomes.

This figure illustrates three of the four major lipid mediator bioactive metabolomes.

Molecules illustrated here represent the flux down of each of the biosynthetic metabolomes from substrate to bioactive mediator to further metabolites, which may or may not retain function. Measuring the levels of these molecules in tissues provides a snapshot of the dynamic biochemical processes occurring at the site and therefore provide an insight into the inflammation-resolution status. Rv = Resolvin, LX = Lipoxin, MaR = Maresin, PD= Protectin, LT = Leukotriene, PG = Prostaglandin and Tx = Thromboxane.